Solid Biosciences (SLDB) Q3 2025 earnings summary

Executive summary

• SGT-003, a gene therapy candidate for Duchenne muscular dystrophy, demonstrated strong interim clinical results, with 23 participants dosed as of October 31, 2025, all showing microdystrophin expression and biomarker improvements.

• SGT-003 was generally well tolerated, with most adverse events mild to moderate; one serious immune-mediated myositis event resolved with steroid treatment.

• SGT-212 and SGT-501 clinical trials were initiated in 2025 following FDA clearances, and SGT-601 remains in preclinical studies.

• Net loss increased year-over-year due to higher R&D and personnel costs, primarily from SGT-003 clinical and manufacturing activities.

• Pipeline progress includes first clinical sites activated for SGT-212 (FALCON, FA) and SGT-501 (ARTEMIS, CPVT) trials.

Financial highlights

• Net loss for Q3 2025 was $45.8 million, up from $32.7 million in Q3 2024; nine-month net loss was $124.5 million, up from $82.1 million.

• R&D expenses for Q3 2025 were $38.9 million, up 42% year-over-year, mainly due to SGT-003 costs.

• Cash, cash equivalents, and available-for-sale securities totaled $236.1 million as of September 30, 2025, supporting operations into H1 2027.

• No product revenue generated; operations funded by equity offerings and private placements.

• Net loss per share for Q3 2025 was $0.48, compared to $0.79 in Q3 2024.

Outlook and guidance

• By early 2026, SGT-003 dosing is expected to reach 30 participants, with a Phase 3 randomized, placebo-controlled, ex-US trial (IMPACT DUCHENNE) underway.

• FDA meeting for SGT-003 registrational pathway planned for H1 2026, with additional data and comparator analysis to be generated.

• Current cash position expected to fund operations into H1 2027, but additional capital will be needed for long-term development and commercialization.

• Ongoing and planned clinical trials for SGT-003, SGT-212, and SGT-501 will drive increased expenses.

• Continued development of next-generation capsid and promoter libraries, with cardiac capsid selection expected in H1 2026.